Biomarkers Market Size, Share, Growth Analysis, By Product & Service(Consumables (Assay Kits, Reagents & Chemicals, Columns & Filters), Services), By Type(Safety Biomarkers, Efficacy Biomarkers (Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamic Biomarkers), By Research Area(Genomics, Proteomics, Metabolomics, and Other Research Areas), By Technology(Immunoassays (ELISA, Protein Microarrays, Western Blot), NGS), By Disease Indication(Cancer, Infectious Diseases, Immunological Disorders, Neurological Disorders), By Application(Clinical Diagnostics, Drug Discovery & Development, Personalized Medicine, Clinical Research), By End User(Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Other End Users), By Region - Industry Forecast 2024-2031

Global Biomarkers Market size was valued at USD 66.97 Billion in 2022 and is poised to grow from USD 75.88 Billion in 2023 to USD 206.04 Billion by 2031, at a CAGR of 13.3% over the forecast period (2024–2031).

Biomarkers Market providers need to focus on maximizing their business scope by reaching into new markets and developing biomarkers for different industrial and personal uses. Raising new capital to fund their R&D and business expansion efforts will be essential for new biomarkers companies going forward. The development of custom robots for specific applications across different industry verticals will also help companies expand their sales potential in the future.  'Hoffmann-La Roche AG (Switzerland)', 'Thermo Fisher Scientific Inc. (United States)', 'Agilent Technologies, Inc. (United States)', 'QIAGEN N.V. (Netherlands)', 'Bio-Rad Laboratories, Inc. (United States)', 'Merck & Co., Inc. (United States)', 'PerkinElmer, Inc. (United States)', 'Illumina, Inc. (United States)', 'BD (Becton, Dickinson and Company) (United States)', 'Myriad Genetics, Inc. (United States)', 'Siemens Healthineers AG (Germany)', 'Danaher Corporation (United States)', 'Biomerieux SA (France)', 'Waters Corporation (United States)', 'Abbott Laboratories (United States)', 'Sysmex Corporation (Japan)', 'Bio-Techne Corporation (United States)', 'Charles River Laboratories International, Inc. (United States)', 'Eurofins Scientific SE (Luxembourg)', 'Pacific Biomarkers (United States)'

There is an increased demand for personalized or tailored treatment depending on individual patient needs and his/her genetic profiles, which is dependent on biomarkers to enhance therapy. Hence, the demand for biomarkers has been fueling at a faster rate in the past few years. Also, expanding research activities in biotechnology and molecular biology is aiding the discovery of new biomarkers and their uses in different domains.

Growing Use of Vitality Biomarkers: Vitality biomarkers help medical professionals to measure a patient’s health before they experience any symptoms. This allows early mediation and prevents the progression of health issues. In addition, IoT devices and wearables are democratizing these improvements by tracking crucial health factors in real-time. Moreover, these devices offer rich datasets and enhance the diagnostics quality.

Region-wise, North America held maximum share of the market in the past years and is expected to hold dominant share in future as well due to the prevalence of advanced healthcare infrastructure and increasing investments in biomarkers for more advancements. Key nations like Canada and the United States hold a mature and well-developed healthcare infrastructure comprising better diagnostic laboratories, superior research facilities, and a strong healthcare system. This infrastructure aids extensive research and development of biomarkers. Also, heavy investments from both private and public sectors are propelling R&D in North America. The leading companies operating in the region include Bio-Rad Laboratories, Inc., Abbott, Thermo Fisher Scientific, Agilent Technologies Inc., and more.